Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03969212




Registration number
NCT03969212
Ethics application status
Date submitted
29/05/2019
Date registered
31/05/2019
Date last updated
23/05/2024

Titles & IDs
Public title
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
Scientific title
A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts
Secondary ID [1] 0 0
2018-004056-37
Secondary ID [2] 0 0
MV40618
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Baloxavir Marboxil
Treatment: Drugs - Placebo

Experimental: Baloxavir Marboxil - Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.

Placebo comparator: Placebo - Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.


Treatment: Drugs: Baloxavir Marboxil
IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.

Treatment: Drugs: Placebo
IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Virological Transmission by Day 5
Timepoint [1] 0 0
Baseline to Day 5 (5 days)
Secondary outcome [1] 0 0
Symptomatic Transmission by Day 5
Timepoint [1] 0 0
Baseline to Day 5 (5 days)
Secondary outcome [2] 0 0
Virological Transmission at the Household Level by Day 5
Timepoint [2] 0 0
Baseline to Day 5 (5 days)
Secondary outcome [3] 0 0
Symptomatic Transmission at the Household Level by Day 5
Timepoint [3] 0 0
Baseline to Day 5 (5 days)
Secondary outcome [4] 0 0
Virological Transmission by Day 9
Timepoint [4] 0 0
Baseline to Day 9 (9 days)
Secondary outcome [5] 0 0
Symptomatic Transmission by Day 9
Timepoint [5] 0 0
Baseline to Day 9 (9 Days)
Secondary outcome [6] 0 0
Any Virological Infection by Day 9
Timepoint [6] 0 0
Baseline to Day 9 (9 Days)
Secondary outcome [7] 0 0
Any Virological Infection at the Household Level by Day 9
Timepoint [7] 0 0
Baseline to Day 9 (9 Days)
Secondary outcome [8] 0 0
Any Symptomatic Infection by Day 9
Timepoint [8] 0 0
Baseline to Day 9 (9 Days)
Secondary outcome [9] 0 0
Any Symptomatic Infection at the Household Level by Day 9
Timepoint [9] 0 0
Baseline to Day 9 (9 Days)
Secondary outcome [10] 0 0
Percentage of IPs With Adverse Events (AEs)
Timepoint [10] 0 0
Baseline to Day 9 (for IPs =12 years old) and Day 21 (for IPs <12 years old)
Secondary outcome [11] 0 0
Percentage of IPs (<= 12 years old) Reporting each Palatability and Acceptability Response
Timepoint [11] 0 0
Baseline

Eligibility
Key inclusion criteria
INCLUSION CRITERIA:

Index Patients (IPs):

* Able to comply with the study protocol per investigator judgment.
* Diagnosed with acute influenza infection by investigator.
* Polymerase chain reaction [PCR] (+) or Rapid Influenza Diagnostic Test [RIDT] (+) for influenza A/B based on cobas® SARS-CoV-2 and influenza A/B or other point-of-care / local laboratory results.
* PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B test or other point-of-care / local laboratory result
* Presence of (a) fever (>=38.0 °C per tympanic or rectal thermometer; >=37.5 °C per axillary, oral or forehead/temporal thermometer) or (b) any influenza symptoms (cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue).
* The time interval between the onset of fever or influenza symptoms and the pre-dose examinations is 48 hours or less.
* IP lives in a household where: (1) No HHC is known to have been diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional (HCP) in the past 4 weeks; (2) All HHCs are expected to meet the key HHC inclusion criteria; (3) >=1 HHCs are expected to participate in the full study who have not received the influenza vaccine within 6 months prior to screening.
* Women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures specified in the protocol

All HHCs (Part 1):

* PCR (-) or RIDT (-) based on cobas® SARS-CoV-2 and influenza A/B or other local point-of-care / local laboratory result.
* PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B or other POC / local laboratory result.
* HHC lives with no HHC who will be present in the home at any time during the study and who meets any HHC exclusion criteria.
* HHC lives with no HHC who does not meet HHC inclusion criteria (part 1).
* HHC lives in a household where =1 HHCs meet all of the following: Start screening within 24 hours after IP randomization; Have NOT received the influenza vaccine within 6 months prior to screening; and Fulfill full study HHC inclusion criteria part 2.

Full study HHCs (part 2) intended for full study must meet the following additional criteria for study entry:

* Agree to participate in the full study.
* Able to comply with the study protocol per investigator judgment
* No influenza symptoms within 7 days prior to screening. Alternatively, mild symptoms are permissible if determined by the investigator to be due to a preexisting condition.
* Temperature <38.0 °C (tympanic).
* Will reside in the index patient's house for at least 7 of the next 9 days and will be present for scheduled study visits.
* Willing and able to measure and record temperature, or have another household member perform the task on his or her behalf. Furthermore, a responsible adult will assume responsibility to oversee or perform this task on behalf of minors.
* In the 6 months prior to screening: a) Has not been diagnosed with influenza by a healthcare professional b) Has not received BXM, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine.
* Does not have a moderate or worse active infections OR infections requiring systemic (e.g., oral or intravenous) or otherwise internally administered (e.g., inhaled, intrathecal) antibiotic/antiviral/antifungal therapy, (topical therapies for mild external infections allowed).

EXCLUSION CRITERIA:

IPs:

* IPs with severe influenza virus infection requiring inpatient treatment.
* IPs judged by the investigator to be at high risk for complications of influenza.
* IP is =12 years old and unable to swallow tablets (not applicable to IPs 5 to 11 year olds who will receive oral suspension).
* Women who are breastfeeding or have a positive pregnancy test in the pre-dose examinations.
* IPs with concurrent (non-influenza) infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations.
* IPs who have received baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine, or an investigational drug, within 30 days or 5 drug-elimination half-lives, whichever is longer, prior to screening.
* IPs who have received an investigational monoclonal antibody for a viral disease in the last year.
* Known hypersensitivity to baloxavir marboxil or the drug product excipients.
* IP previously included in the study
* IP lives with an HHC who, based on available information, meets the HHC exclusion criteria

HHC:

* Pregnant or within 2 weeks post-partum at screening.
* Immunocompromised.
* Less than 2 years old.
* Who have received an investigational therapy within the 30 days or 5 drug elimination half-lives, whichever is longer, prior to screening.
* Diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional in the past 4 weeks.
* HHC who plans to arrive home after 24 hours post IP randomization to Day 9 and is not willing to be consented as soon as possible upon arrival.
* HHC previously included in the study.
Minimum age
5 Years
Maximum age
64 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/10/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/05/2024
Sample size
Target
Accrual to date
Final
4176
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Montana
Country [10] 0 0
United States of America
State/province [10] 0 0
Nevada
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Dupnitsa
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Kozloduy
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Montana
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Pleven
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Ruse
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sevlievo
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Sliven
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
China
State/province [24] 0 0
Beijing City
Country [25] 0 0
China
State/province [25] 0 0
Beijing
Country [26] 0 0
China
State/province [26] 0 0
Chengdu
Country [27] 0 0
China
State/province [27] 0 0
Guangzhou
Country [28] 0 0
China
State/province [28] 0 0
Liaocheng City
Country [29] 0 0
China
State/province [29] 0 0
Nanjing City
Country [30] 0 0
China
State/province [30] 0 0
Sanya
Country [31] 0 0
China
State/province [31] 0 0
Shanghai
Country [32] 0 0
China
State/province [32] 0 0
Shenzhen City
Country [33] 0 0
China
State/province [33] 0 0
Shenzhen
Country [34] 0 0
China
State/province [34] 0 0
Taizhou City
Country [35] 0 0
China
State/province [35] 0 0
Wenzhou
Country [36] 0 0
China
State/province [36] 0 0
Wuhan City
Country [37] 0 0
China
State/province [37] 0 0
Yinchuan
Country [38] 0 0
China
State/province [38] 0 0
Zhengzhou
Country [39] 0 0
China
State/province [39] 0 0
ZIbo
Country [40] 0 0
Costa Rica
State/province [40] 0 0
San José
Country [41] 0 0
Greece
State/province [41] 0 0
Athens
Country [42] 0 0
Greece
State/province [42] 0 0
Chaidari
Country [43] 0 0
Hungary
State/province [43] 0 0
Budapest
Country [44] 0 0
Hungary
State/province [44] 0 0
Hosszúhetény
Country [45] 0 0
Hungary
State/province [45] 0 0
Nyíregyháza
Country [46] 0 0
Hungary
State/province [46] 0 0
Zalaegerszeg
Country [47] 0 0
India
State/province [47] 0 0
Delhi
Country [48] 0 0
India
State/province [48] 0 0
Gujarat
Country [49] 0 0
India
State/province [49] 0 0
Haryana
Country [50] 0 0
India
State/province [50] 0 0
Karnataka
Country [51] 0 0
India
State/province [51] 0 0
Maharashtra
Country [52] 0 0
India
State/province [52] 0 0
Rajasthan
Country [53] 0 0
India
State/province [53] 0 0
Telangana
Country [54] 0 0
India
State/province [54] 0 0
Uttar Pradesh
Country [55] 0 0
India
State/province [55] 0 0
WEST Bengal
Country [56] 0 0
Israel
State/province [56] 0 0
Beer-Sheva
Country [57] 0 0
Israel
State/province [57] 0 0
Kiryat Motzkin
Country [58] 0 0
Israel
State/province [58] 0 0
Petach Tikva
Country [59] 0 0
Israel
State/province [59] 0 0
Tel Aviv
Country [60] 0 0
Japan
State/province [60] 0 0
Akashi
Country [61] 0 0
Japan
State/province [61] 0 0
Chikushino
Country [62] 0 0
Japan
State/province [62] 0 0
Date
Country [63] 0 0
Japan
State/province [63] 0 0
Fukuoka
Country [64] 0 0
Japan
State/province [64] 0 0
Fukuyama
Country [65] 0 0
Japan
State/province [65] 0 0
Hakodate
Country [66] 0 0
Japan
State/province [66] 0 0
Hanno
Country [67] 0 0
Japan
State/province [67] 0 0
Ichikawa
Country [68] 0 0
Japan
State/province [68] 0 0
Kagoshima
Country [69] 0 0
Japan
State/province [69] 0 0
Kashiwa
Country [70] 0 0
Japan
State/province [70] 0 0
Kasugai
Country [71] 0 0
Japan
State/province [71] 0 0
Kasuyagun
Country [72] 0 0
Japan
State/province [72] 0 0
Kawasaki
Country [73] 0 0
Japan
State/province [73] 0 0
Kitakyushu
Country [74] 0 0
Japan
State/province [74] 0 0
Kita
Country [75] 0 0
Japan
State/province [75] 0 0
Kochi
Country [76] 0 0
Japan
State/province [76] 0 0
Kodaira
Country [77] 0 0
Japan
State/province [77] 0 0
Musashino
Country [78] 0 0
Japan
State/province [78] 0 0
Nagoya,
Country [79] 0 0
Japan
State/province [79] 0 0
Naha
Country [80] 0 0
Japan
State/province [80] 0 0
Nonoichi
Country [81] 0 0
Japan
State/province [81] 0 0
Oita
Country [82] 0 0
Japan
State/province [82] 0 0
Osaka
Country [83] 0 0
Japan
State/province [83] 0 0
Saga
Country [84] 0 0
Japan
State/province [84] 0 0
Saitama
Country [85] 0 0
Japan
State/province [85] 0 0
Sapporo
Country [86] 0 0
Japan
State/province [86] 0 0
Sendai
Country [87] 0 0
Japan
State/province [87] 0 0
Shinagawa
Country [88] 0 0
Japan
State/province [88] 0 0
Tokorozawa
Country [89] 0 0
Japan
State/province [89] 0 0
Tokyo
Country [90] 0 0
Japan
State/province [90] 0 0
Toshima
Country [91] 0 0
Japan
State/province [91] 0 0
Toyohashi
Country [92] 0 0
Japan
State/province [92] 0 0
Tsuchiura
Country [93] 0 0
Japan
State/province [93] 0 0
Tsuru
Country [94] 0 0
Japan
State/province [94] 0 0
Urasoe
Country [95] 0 0
Japan
State/province [95] 0 0
Yotsukaido
Country [96] 0 0
Mexico
State/province [96] 0 0
Jalisco
Country [97] 0 0
Mexico
State/province [97] 0 0
Mexico CITY (federal District)
Country [98] 0 0
Mexico
State/province [98] 0 0
Nuevo LEON
Country [99] 0 0
Mexico
State/province [99] 0 0
Queretaro
Country [100] 0 0
Mexico
State/province [100] 0 0
Yucatan
Country [101] 0 0
New Zealand
State/province [101] 0 0
Hamilton
Country [102] 0 0
New Zealand
State/province [102] 0 0
Rotorua
Country [103] 0 0
New Zealand
State/province [103] 0 0
Wellington
Country [104] 0 0
Poland
State/province [104] 0 0
Bia?ystok
Country [105] 0 0
Poland
State/province [105] 0 0
Bydgoszcz
Country [106] 0 0
Poland
State/province [106] 0 0
Chojnice
Country [107] 0 0
Poland
State/province [107] 0 0
Kalisz
Country [108] 0 0
Poland
State/province [108] 0 0
Piaseczno
Country [109] 0 0
Poland
State/province [109] 0 0
Piotrków Trybunalski
Country [110] 0 0
Poland
State/province [110] 0 0
Pu?awy
Country [111] 0 0
Poland
State/province [111] 0 0
Zabrze
Country [112] 0 0
Puerto Rico
State/province [112] 0 0
San Juan
Country [113] 0 0
Singapore
State/province [113] 0 0
Singapore
Country [114] 0 0
South Africa
State/province [114] 0 0
Cape Town
Country [115] 0 0
South Africa
State/province [115] 0 0
Groenkloof
Country [116] 0 0
South Africa
State/province [116] 0 0
Johannesburg
Country [117] 0 0
South Africa
State/province [117] 0 0
Kraaifontein
Country [118] 0 0
South Africa
State/province [118] 0 0
Midrand
Country [119] 0 0
Spain
State/province [119] 0 0
Madrid
Country [120] 0 0
Turkey
State/province [120] 0 0
Ankara
Country [121] 0 0
Turkey
State/province [121] 0 0
Antalya
Country [122] 0 0
Turkey
State/province [122] 0 0
Istanbul
Country [123] 0 0
Turkey
State/province [123] 0 0
Izmir
Country [124] 0 0
Turkey
State/province [124] 0 0
Kocaeli
Country [125] 0 0
Turkey
State/province [125] 0 0
Trabzon
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Harrow

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 1 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms.
Trial website
https://clinicaltrials.gov/study/NCT03969212
Trial related presentations / publications
Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, Ajisawa Y, Iwata S, Watanabe H, Honda K, Kitanishi Y, Hara K, Mukae H. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study. Clin Infect Dis. 2021 Jun 1;72(11):e859-e867. doi: 10.1093/cid/ciaa1622.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03969212